Diabetes & Obesity Drugs Show Promise in Combating Addiction, New Study Finds
A new study published in the Journal of the Endocrine Society suggests that medications already widely used to treat diabetes and obesity may offer a novel approach to tackling alcohol and drug addiction. These drugs, known as Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs), are generating excitement as a potential breakthrough in addressing substance use disorders.
Fewer than one in four individuals struggling with alcohol or other substance use disorders received treatment in 2023, highlighting a critical gap in care. Current treatment options are often limited by stigma and a lack of accessible resources, leaving a significant public health need unmet. “Current treatments for [alcohol and other substance use disorders] fall short of addressing public health needs,” researchers noted.
Understanding the Link Between Metabolism and Addiction
The potential of GLP-1RAs lies in their multifaceted effects on the body, extending beyond their well-known impact on appetite and weight loss. These medications work by activating GLP-1 receptors in the central nervous system, which play a key role in regulating hunger signals. However, scientists are increasingly recognizing a complex interplay between metabolic processes and addictive behaviors.
The study points to shared biological and neurological characteristics between obesity and addiction, suggesting that pathways implicated in compulsive overeating may also contribute to substance use disorders. “Pathways implicated in addiction also contribute to pathological overeating and obesity,” one researcher explained. This overlap has prompted investigation into whether GLP-1 drugs, successful in managing weight, could also influence the brain circuits driving addictive behaviors.
Early Research Shows Encouraging Results
Initial studies, conducted in both animal models and human trials, offer a glimmer of hope. A lead researcher from the National Institute on Drug Abuse (NIDA) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) stated, “Early research in both animals and humans suggests that these treatments may help reduce alcohol and other substance use.”
Here’s a breakdown of the findings across different substance use disorders:
- Alcohol Use Disorder (AUD): While an initial trial with exenatide, the first approved GLP-1 receptor agonist, showed no significant overall effect on alcohol consumption, a secondary analysis revealed reduced intake among individuals with AUD and comorbid obesity. More recently, a trial using semaglutide – a newer GLP-1RA approved for both diabetes and obesity – demonstrated a reduction in laboratory-measured alcohol self-administration, drinks per drinking day, and cravings.
- Opioid Use Disorder: In rodent models, several GLP-1 receptor agonists have been shown to reduce self-administration of heroin, fentanyl, and oxycodone. These medications also appear to reduce the likelihood of drug-seeking reinstatement, a model for relapse in addiction.
- Tobacco Use Disorder: Preclinical data indicate that GLP-1 receptor agonists can reduce nicotine self-administration and the reinstatement of nicotine-seeking behavior in rodents. Early clinical trials suggest a potential for these medications to lower the number of cigarettes smoked per day and mitigate weight gain often associated with smoking cessation.
The Path Forward: More Research Needed
Despite the promising early findings, researchers emphasize the need for further investigation. “This research is very important because alcohol and drug addiction are major causes of illness and death, yet there are still only a few effective treatment options,” a senior official stated. “Finding new and better treatments is critically important to help people live healthier lives.”
The team, including researchers from the University of Galway, NIDA, NIAAA, the University of Milan, and Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, is focused on confirming the efficacy of GLP-1 drugs in treating addiction and unraveling the underlying biological mechanisms. While questions remain, the initial evidence suggests a potentially transformative new direction in the fight against substance use disorders.
